31951-12-9

Basic information

• Product Name: 3-nitro-4-tert-butylaniline
• Synonyms: 3-nitro-4-tert-butylaniline;BenzenaMine, 4-(1,1-diMethylethyl)-3-nitro-;4-(TERT-BUTYL)-3-NITROANILINE
• CAS NO: 31951-12-9
• Molecular Formula: C₁₀H₁₄N₂O₂
• Molecular Weight: 194.23036
• Mol File: 31951-12-9.mol
• Article Data: 12

Chemical Properties

• Melting Point: 58-59 °C
• Boiling Point: 336°Cat760mmHg
• Flash Point: 157°C
• Appearance: /
• Density: 1.14g/cm³
• Vapor Pressure: 0.000115mmHg at 25°C
• Refractive Index: 1.564
• PKA: 3.02±0.10(Predicted)
• CAS DataBase Reference: 3-nitro-4-tert-butylaniline(CAS DataBase Reference)
• NIST Chemistry Reference: 3-nitro-4-tert-butylaniline(31951-12-9)
• EPA Substance Registry System: 3-nitro-4-tert-butylaniline(31951-12-9)

Safety Data

• Hazardous Substances Data: 31951-12-9(Hazardous Substances Data)

Usage

General Description

3-nitro-4-tert-butylaniline is a chemical compound with the molecular formula C10H14N2O2. It is a nitro substituted aniline compound that is commonly used as an intermediate in the synthesis of various organic chemicals. The "3-nitro" indicates the presence of a nitro group (NO2) on the third carbon of the benzene ring, while "4-tert-butyl" signifies the presence of a tert-butyl group (C4H9) on the fourth carbon. 3-nitro-4-tert-butylaniline is known for its versatility in organic synthesis and is often used in the production of dyes, pharmaceuticals, and agrochemicals. It is important to handle this compound with caution as it can pose health and environmental risks if not properly managed. Additionally, it is important to consult the safety data sheet and follow proper handling protocols when working with 3-nitro-4-tert-butylaniline.

InChI:InChI=1/C10H14N2O2/c1-10(2,3)8-5-4-7(11)6-9(8)12(13)14/h4-6H,11H2,1-3H3

Upstream product

• 253185-03-4 tert-butylbenzene 
• 103853-71-0 4-tert-butyl-3-nitro-benzoic acid amide 
• 4160-54-7 1-tert-butyl-2,4-dinitrobenzene 
• 769-92-6 4-tert-Butylaniline 
• 59719-78-7 4-tert-butyl-3-nitrobenzoic acid 
• 3282-56-2 4-tert-butylnitrobenzene 

Downstream Products

• 62171-59-9 1-(tert-butyl)-2-iodobenzene 
• 6310-21-0 2-(1,1-dimethylethyl)-benzenamine 
• 453560-57-1 N-(3-bromo-5-trifluoromethyl-phenyl)-acetamide 
• 1886-57-3 1-tert-butyl-2-nitrobenzene 
• 873055-92-6 (3-amino-4-tert-butylphenyl)carbamic acid tert-butyl ester 
• 873055-91-5 (4-tert-butyl-3-nitrophenyl)carbamic acid tert-butyl ester 
• 36919-89-8 di(tert-butyl)-biphenyl 
• 2025-23-2 2,3-dinitro-4-t-butylaniline 
• 166263-22-5 N-cyano-N'-<5-cyano-2-(1,1-dimethylethyl)phenyl>carbamimidic acid phenyl ester 
• 166263-23-6 N'-<5-cyano-2-(1,1-dimethylethyl)phenyl>carbamic acid phenyl ester 
• 166263-20-3 3-amino-4-(1,1-dimethylethyl)benzonitrile 

Relevant articles and documents

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE

The present invention provides classes of compounds, including-their pharmaceutically acceptable derivatives, useful for treating angiogenesis and related diseases such as cancer. Formula I and II wherein R is a 9- or 10-membered heterocyclyl ring selected from 7-isoquinolinyl,..2-methyl-3-oxo-2,3-dihydroindazol-6-yl, [1,6]-naphthydrin-3-yl, [1,7]-naphthydrin-2-yl, 1-oxo-2,3-dihydrobenzofuran-4-yl, 3-oxo-2,3-dihydrobenzofuran-5-yl, dihydro-benzodioxinyl, 6-quinazolinyl, 2-amino-6-quinazolinyl, 4-methylamino-6-quinazolinyl, 2,4-diamino-6 quinazolinyl, 3-oxo-3,4-dihydro-1,4-benzoxazin-6-yl, 2,2-difluoro-l;3-benzodioxol-5-yl and 2,2,3,3 tetrafluoro-2,3-dihydro-l,4-benzodioxin-6-yl, each of which is optionally substituted with one or more substituents selected from halo, haloakyl, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, N-dimethylamino-C1-6-alkyl, N-dimethylamino-C1-6-alkoxy, amino, alkyl-carbonylamino, morpholino-sulfonyl, amino-sulfonyl, oxazolyl, pyrrolyl,4 morpholinyl, carboxyl, cyano, and acetyl; wherein R1 in formula I is selected from unsubstituted or substituted phenyl, 5-6 membered heteroaryl, 9-10 membered bicyclic heterocyclyl and 11-14 membered tricyclic heterocyclyl, and R1 in formula II is selected from specific bicyclic heterocycles.

SUBSTITUTED ANTHRANILIC AMIDE DERIVATIVES AND METHODS OF USE

Selected compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.